LSC
SUPN icon

Lyon Street Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Lyon Street Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-55,047
Closed -$2.2M – 58
2017
Q3 		$2.2M Buy
+55,047
New +$2.38M 0.85% 45

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Lyon Street Capital's SUPN Position: Q4 2017 in Review

Lyon Street Capital sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 55,047 shares — an estimated $2.2M sold.

Lyon Street Capital first reported a position in SUPN in Q3 2017 and held it in 1 quarter. The position peaked at $2.2M in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Lyon Street Capital reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Lyon Street Capital sold 55,047 Supernus Pharmaceuticals shares in Q4 2017, an estimated $2.2M.
  • Lyon Street Capital first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Lyon Street Capital's Supernus Pharmaceuticals position peaked at $2.2M in Q3 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Lyon Street Capital's 13F filing for Q4 2017, filed 14 Feb 2018.